{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T21:32:32Z","timestamp":1793568752685,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.arcmed.2023.102884","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:29:19Z","timestamp":1693549759000},"page":"102884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Pegvisomant in the Treatment of Acromegaly"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4464-0427","authenticated-orcid":false,"given":"Linus","family":"Haberbosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Strasburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2023.102884_bib0001","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1530\/EJE-21-0216","article-title":"Global epidemiology of acromegaly: a systematic review and meta-analysis","volume":"185","author":"Crisafulli","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0002","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0003","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1210\/jc.2007-2149","article-title":"Changing patterns in diagnosis and therapy of acromegaly over two decades","volume":"93","author":"Nachtigall","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0004","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: A consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0005","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0006","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11102-010-0272-1","article-title":"Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR","volume":"14","author":"Vilar","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102884_bib0007","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1530\/EJE-14-0844","article-title":"Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey","volume":"172","author":"Schofl","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0008","doi-asserted-by":"crossref","DOI":"10.1126\/science.1249783","article-title":"Mechanism of activation of protein kinase JAK2 by the growth hormone receptor","volume":"344","author":"Brooks","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.arcmed.2023.102884_bib0009","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1073\/pnas.87.13.5061","article-title":"Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice","volume":"87","author":"Chen","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arcmed.2023.102884_bib0010","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1073\/pnas.88.8.3407","article-title":"Rational design of receptor-specific variants of human growth hormone","volume":"88","author":"Cunningham","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arcmed.2023.102884_bib0011","first-page":"1716","article-title":"Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer","volume":"8","author":"Ross","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0012","first-page":"4013","article-title":"Effects of estradiol and exogenous insulin-like growth factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism","volume":"83","author":"Wilson","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0013","first-page":"2098","article-title":"Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH","volume":"84","author":"Thorner","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0014","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2023.102884_bib0015","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"issue":"Suppl 5","key":"10.1016\/j.arcmed.2023.102884_bib0016","first-page":"70","article-title":"Experience from the German pegvisomant observational study","volume":"68","author":"Strasburger","year":"2007","journal-title":"Horm Res"},{"key":"10.1016\/j.arcmed.2023.102884_bib0017","first-page":"328","article-title":"Brazilian multicenter study on pegvisomant treatment in acromegaly","volume":"63","author":"Boguszewski","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0018","doi-asserted-by":"crossref","first-page":"320","DOI":"10.20945\/2359-3997000000160","article-title":"Pegvisomant in acromegaly: a multicenter real-life study in Argentina","volume":"63","author":"Basavilbaso","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0019","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1507\/endocrj.EJ19-0266","article-title":"Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance","volume":"67","author":"Yamaguchi","year":"2020","journal-title":"Endocr J"},{"issue":"Suppl 5","key":"10.1016\/j.arcmed.2023.102884_bib0020","first-page":"68","article-title":"ACROSTUDY: an overview","volume":"68","author":"Trainer","year":"2007","journal-title":"Horm Res"},{"key":"10.1016\/j.arcmed.2023.102884_bib0021","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0022","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12020-018-1729-7","article-title":"Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies","volume":"63","author":"Leonart","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102884_bib0023","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11102-022-01206-2","article-title":"Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience","volume":"25","author":"Salvatori","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102884_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101684","article-title":"Second line treatment of acromegaly: Pasireotide or Pegvisomant?","volume":"36","author":"Chiloiro","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0025","doi-asserted-by":"crossref","first-page":"D17","DOI":"10.1530\/EJE-19-0998","article-title":"Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly","volume":"182","author":"van der Lely","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102884_bib0027","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0028","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0029","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40618-017-0773-0","article-title":"How to improve effectiveness of pegvisomant treatment in acromegalic patients","volume":"41","author":"Ragonese","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.arcmed.2023.102884_bib0030","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0031","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1210\/jc.2008-0027","article-title":"A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly","volume":"93","author":"Murray","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0032","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0033","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12020-021-02782-2","article-title":"Long-term safety and efficacy of long-acting pasireotide in acromegaly","volume":"74","author":"Akirov","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102884_bib0034","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0035","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-2265.2001.01374.x","article-title":"Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion","volume":"55","author":"Muller","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102884_bib0036","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/cen.12239","article-title":"Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly","volume":"80","author":"Madsen","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102884_bib0037","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/eje.1.02341","article-title":"Pegvisomant interference in GH assays results in underestimation of GH levels","volume":"156","author":"Paisley","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0038","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1373\/clinchem.2012.188128","article-title":"Automated 22-kD growth hormone-specific assay without interference from Pegvisomant","volume":"58","author":"Manolopoulou","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.arcmed.2023.102884_bib0039","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/cen.14468","article-title":"Insulin-like growth factor-1, growth hormone and disease outcomes in acromegaly: A population study","volume":"95","author":"Thomas","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102884_bib0040","first-page":"3419","article-title":"Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly","volume":"83","author":"Swearingen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0041","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1530\/EJE-19-0794","article-title":"All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis","volume":"182","author":"Tritos","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0042","doi-asserted-by":"crossref","first-page":"L5","DOI":"10.1530\/EJE-19-0509","article-title":"Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis","volume":"181","author":"Bolfi","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0043","first-page":"30","article-title":"Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies","volume":"15","author":"Varlamov","year":"2019","journal-title":"Eur Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0044","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/BF03346667","article-title":"The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues","volume":"33","author":"De Martino","year":"2010","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.arcmed.2023.102884_bib0045","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1210\/jcem.86.11.7987","article-title":"Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency","volume":"86","author":"Muller","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0046","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2018-02281","article-title":"Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies","volume":"104","author":"Feola","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0047","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12020-018-1792-0","article-title":"Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy","volume":"63","author":"Brue","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102884_bib0048","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","article-title":"Current and Emerging Aspects of Diabetes Mellitus in Acromegaly","volume":"27","author":"Frara","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0049","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/EJE-13-0438","article-title":"Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels","volume":"171","author":"Droste","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/EJE-13-0032","article-title":"Effects of medical therapies for acromegaly on glucose metabolism","volume":"169","author":"Urbani","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0051","doi-asserted-by":"crossref","first-page":"E1010","DOI":"10.1152\/ajpendo.2000.278.6.E1010","article-title":"Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum","volume":"278","author":"Hansen","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0052","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40618-017-0614-1","article-title":"Pegvisomant in acromegaly: an update","volume":"40","author":"Giustina","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.arcmed.2023.102884_bib0053","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/edrv-8-2-115","article-title":"Effect of growth hormone on carbohydrate and lipid metabolism","volume":"8","author":"Davidson","year":"1987","journal-title":"Endocr Rev"},{"key":"10.1016\/j.arcmed.2023.102884_bib0054","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","article-title":"Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant","volume":"87","author":"Sesmilo","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0055","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1530\/EJE-11-0408","article-title":"Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study","volume":"165","author":"Colao","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0056","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000371818","article-title":"The metabolic risk in patients newly diagnosed with acromegaly is related to fat distribution and circulating adipokines and improves after treatment","volume":"103","author":"Olarescu","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2023.102884_bib0057","doi-asserted-by":"crossref","first-page":"dgz096","DOI":"10.1210\/clinem\/dgz096","article-title":"A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0058","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1530\/EJE-15-0500","article-title":"Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study","volume":"173","author":"Kuhn","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0059","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1530\/EJE-09-0694","article-title":"Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly","volume":"161","author":"Berg","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0060","doi-asserted-by":"crossref","first-page":"dgz116","DOI":"10.1210\/clinem\/dgz116","article-title":"Obstructive Sleep Apnea in Acromegaly and the Effect of Treatment: A Systematic Review and Meta-Analysis","volume":"105","author":"Parolin","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0061","first-page":"141","article-title":"Obstructive Sleep Apnea Syndrome Is Less Frequent in Patients With Well-Controlled Acromegaly Treated With Somatostatin Analogues, Pegvisomant or in Combination","volume":"7","author":"Herrmann","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0062","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.577173","article-title":"Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes","volume":"11","author":"Vila","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.arcmed.2023.102884_bib0063","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/clc.22867","article-title":"Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management","volume":"41","author":"Sharma","year":"2018","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0064","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/jc.2006-1587","article-title":"Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance","volume":"92","author":"Pivonello","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11102-011-0318-z","article-title":"Improvement of cardiac parameters in patients with acromegaly treated with medical therapies","volume":"15","author":"Colao","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102884_bib0066","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/EJE-12-0596","article-title":"Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias","volume":"168","author":"Auriemma","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0067","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jcph.213","article-title":"Effects of Subcutaneous Pasireotide on Cardiac Repolarization in Healthy Volunteers: a Single-Center, Phase I, Randomized, Four-Way Crossover Study","volume":"54","author":"Breitschaft","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0068","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1210\/jc.2016-3693","article-title":"Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study","volume":"102","author":"Constantin","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0069","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2265.2002.01624.x","article-title":"Effects of a growth hormone receptor antagonist on bone markers in acromegaly","volume":"57","author":"Fairfield","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102884_bib0070","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1210\/jc.2003-030772","article-title":"Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal","volume":"88","author":"Parkinson","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0071","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11102-018-0873-7","article-title":"Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly","volume":"21","author":"Chiloiro","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102884_bib0072","doi-asserted-by":"crossref","first-page":"dgz054","DOI":"10.1210\/clinem\/dgz054","article-title":"Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs","volume":"105","author":"Chiloiro","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0073","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0074","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrendo.2011.39","article-title":"Pituitary tumors: coping with \u2018cured\u2019 pituitary tumors","volume":"7","author":"Webb","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0075","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/cen.13331","article-title":"Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study","volume":"86","author":"Kyriakakis","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102884_bib0076","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ghir.2015.06.008","article-title":"More concerns and stronger beliefs about the necessity of medication in patients with acromegaly are associated with negative illness perceptions and impairment in quality of life","volume":"25","author":"Andela","year":"2015","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.arcmed.2023.102884_bib0077","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s11102-015-0665-2","article-title":"The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL","volume":"18","author":"Yoshida","year":"2015","journal-title":"Pituitary"},{"issue":"Supplement_1","key":"10.1016\/j.arcmed.2023.102884_bib0078","doi-asserted-by":"crossref","DOI":"10.1210\/js.2019-SUN-LB080","article-title":"SUN-LB080 ACROSTUDY-safety and efficacy of a cohort of 110 na\u00efve patients with acromegaly treated with pegvisomant","volume":"3","author":"Wajnrajch","year":"2019","journal-title":"Journal of the Endocrine Society"},{"key":"10.1016\/j.arcmed.2023.102884_bib0079","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11102-019-00986-4","article-title":"Development of a novel patient-reported measure for acromegaly: the Acro-TSQ","volume":"22","author":"Fleseriu","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102884_bib0080","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12020-022-03106-8","article-title":"Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life","volume":"77","author":"Cangiano","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102884_bib0081","first-page":"dgad237","article-title":"Psychopathology in Acromegaly\u2013Real and Perceived","author":"Pivonello","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0082","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s11102-017-0835-5","article-title":"Development of ACRODAT\u00ae, a new software medical device to assess disease activity in patients with acromegaly","volume":"20","author":"van der Lely","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102884_bib0083","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11102-018-00933-9","article-title":"AcroVoice: eliciting the patients\u2019 perspective on acromegaly disease activity","volume":"22","author":"Jackson","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102884_bib0084","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11102-019-00950-2","article-title":"AcroVoice: the controversial values in reflecting acromegaly disease activity","volume":"22","author":"Wang","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102884_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-11-210","article-title":"The case for an international patient-reported outcomes measurement information system (PROMIS\u00ae) initiative","volume":"11","author":"Alonso","year":"2013","journal-title":"Health and quality of life outcomes"},{"issue":"Suppl 1","key":"10.1016\/j.arcmed.2023.102884_bib0086","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1530\/EJE-09-0322","article-title":"ACROSTUDY: the first 5 years","volume":"161","author":"Trainer","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0087","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0088","doi-asserted-by":"crossref","first-page":"E251","DOI":"10.1210\/jc.2010-1742","article-title":"Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study","volume":"96","author":"Marazuela","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0089","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/jc.2009-1239","article-title":"Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study","volume":"95","author":"Buhk","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0090","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00330-004-2531-x","article-title":"Magnetic resonance imaging of pituitary adenomas","volume":"15","author":"Bonneville","year":"2005","journal-title":"Eur Radiol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0091","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/EJE-08-0910","article-title":"Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study","volume":"161","author":"Buchfelder","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0092","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/eje.1.02079","article-title":"Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis","volume":"154","author":"Biering","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0093","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1530\/eje.1.02160","article-title":"Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant","volume":"154","author":"Feenstra","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0094","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11102-019-00943-1","article-title":"Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study","volume":"22","author":"Camara","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102884_bib0095","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1210\/jc.2008-0833","article-title":"Lipodystrophy in patients with acromegaly receiving pegvisomant","volume":"93","author":"Bonert","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0096","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40618-022-01980-7","article-title":"Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience","volume":"46","author":"Pirchio","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.arcmed.2023.102884_bib0097","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/cen.12440","article-title":"Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study","volume":"81","author":"Sesmilo","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102884_bib0098","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/0003-4819-147-10-200711200-00019","article-title":"Pegvisomant-induced lipohypertrophy: report of a case with histopathology","volume":"147","author":"Marazuela","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.arcmed.2023.102884_bib0099","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s13300-016-0187-6","article-title":"Lipodystrophy in insulin-treated subjects and other injection-site skin reactions: are we sure everything is clear?","volume":"7","author":"Gentile","year":"2016","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.arcmed.2023.102884_bib0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/EJE-17-0996","article-title":"Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant","volume":"178","author":"Strasburger","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0101","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(05)63011-5","article-title":"Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly","volume":"365","author":"Feenstra","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2023.102884_bib0102","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1210\/jc.2014-2032","article-title":"Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly","volume":"99","author":"Neggers","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0103","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12902-020-0545-2","article-title":"Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies","volume":"20","author":"Ma","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.arcmed.2023.102884_bib0104","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","article-title":"A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly","volume":"71","author":"Trainer","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102884_bib0105","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12020-014-0393-9","article-title":"ACROSTUDY: the Italian experience","volume":"48","author":"Grottoli","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102884_bib0106","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)","volume":"103","author":"Muhammad","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0107","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102884_bib0108","doi-asserted-by":"crossref","first-page":"dgaa444","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0109","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/jc.2011-2603","article-title":"Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial","volume":"97","author":"Higham","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102884_bib0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11102-012-0382-z","article-title":"Pegvisomant and cabergoline combination therapy in acromegaly","volume":"16","author":"Bernabeu","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102884_bib0111","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11102-016-0782-6","article-title":"Cabergoline in acromegaly","volume":"20","author":"Kuhn","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102884_bib0112","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1472-6823-9-20","article-title":"Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation","volume":"9","author":"Moore","year":"2009","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.arcmed.2023.102884_bib0113","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.745843","article-title":"Cost-Utility of Acromegaly Pharmacological Treatments in a French Context","volume":"12","author":"Brue","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.arcmed.2023.102884_bib0114","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14737167.2019.1610396","article-title":"Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain","volume":"20","author":"Peral","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.arcmed.2023.102884_bib0115","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000507890","article-title":"Pharmacological Acromegaly Treatment: Cost\u2013Utility and Value of Information Analysis","volume":"111","author":"Leonart","year":"2021","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2023.102884_bib0116","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11102-022-01285-1","article-title":"A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly","volume":"26","author":"Fleseriu","year":"2023","journal-title":"Pituitary"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:14:42Z","timestamp":1741184082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440923001224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":116,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0188440923001224"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102884","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Pegvisomant in the Treatment of Acromegaly","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102884"}}